Humana loses bid to challenge downgrade to US Medicare 'star' ratings

A federal judge in Texas dismissed Humana's lawsuit challenging the U.S. government's reduced Medicare star ratings, ruling the insurer failed to exhaust administrative appeals. This decision, which could cost Humana billions in bonus payments and customers, led to a 3.4% decline in its shares and broader drops for other insurers like UnitedHealth and Centene. While Humana plans to explore further legal options, including an appeal or refiling the lawsuit (as the dismissal was without prejudice), analysts largely view the ruling as already priced into the company's 2026 earnings estimates.

Analysis

A federal court's dismissal of Humana's lawsuit against the U.S. Department of Health and Human Services (HHS) has introduced a new layer of uncertainty for the health insurer. The lawsuit, which challenged a reduction in its Medicare Advantage star ratings, was dismissed on procedural grounds because Humana had not yet exhausted its administrative appeal options. This ruling triggered a significant market reaction, with Humana's shares falling approximately 3.4% and peers like UnitedHealth and Centene also declining, signaling sector-wide sensitivity to regulatory outcomes. The financial stakes are high, as the lower ratings could deprive Humana of potentially billions in bonus payments used to fund competitive benefits. However, the dismissal was without prejudice, leaving Humana the option to refile the lawsuit now that the administrative process is complete. Importantly, Mizuho analysts view this legal setback as having been widely expected and already priced into Humana's 2026 earnings estimates and long-term growth forecasts, suggesting the market's negative reaction may be more of a short-term sentiment shift than a fundamental re-evaluation.

Key Decisions for Investors

• Investors should recognize the disconnect between the immediate negative stock performance and analyst views that this outcome was already priced into Humana's long-term forecasts, which could present an opportunity if the market has overreacted.
• It is critical to monitor Humana's subsequent actions, as the company's decision to appeal or refile the lawsuit will be a key catalyst and determine the timeline for resolving the uncertainty around its 2025 bonus payments.
• The contagion effect on shares of UnitedHealth and Centene highlights a systemic risk, suggesting investors should assess the star ratings vulnerability across their entire managed care portfolio, not just for Humana.